CFO & Chief Strategy Officer of Cara Therapeutics Inc (30-Year Financial, Insider Trades) Mani Mohindru (insider trades) sold 37,431 shares of CARA on 07/15/2019 at an average price of $25 a share. The total sale was $935,775.
Cara Therapeutics Inc is an emerging biotechnology company. It is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara Therapeutics Inc has a market cap of $1.07 billion; its shares were traded at around $26.91 with and P/S ratio of 57.25. GuruFocus has detected 4 severe warning signs with Cara Therapeutics Inc. .
CFO Recent Trades:
- CFO & Chief Strategy Officer Mani Mohindru sold 37,431 shares of CARA stock on 07/15/2019 at the average price of $25. The price of the stock has increased by 7.64% since.
Directors and Officers Recent Trades:
- Chief Scientific Off,SVP-R&D Frederique Ph.d. Menzaghi sold 20,000 shares of CARA stock on 07/01/2019 at the average price of $21.9. The price of the stock has increased by 22.88% since.
- Director Jeffrey L. Ives sold 2,500 shares of CARA stock on 07/01/2019 at the average price of $21.75. The price of the stock has increased by 23.72% since.
For the complete insider trading history of CARA, click here
.
